• eFFECTOR and QBI to study anti-viral agent for Covid-19 treatment pharmaceutical-technology
    May 06, 2021
    eFFECTOR Therapeutics and Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), have announced a $5m cooperative agreement for a planned Phase Ib study of zotatifin (eFT226), an anti-viral agent for Covid-19 ...
  • Pfizer signs oncology agreement with STR-focused eFFECTOR pharmaceutical-technology
    January 14, 2020
  • eFFECTOR Therapeutics completes $38.6 million Series C financing biospectrumasia
    August 11, 2017
PharmaSources Customer Service